We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




3D Biophotonic Imaging Software

By Biotechdaily staff writers
Posted on 27 May 2005
A new three-dimensional (3D) software analysis system enables scientists to better visualize, monitor, and determine biologic processes in living animals noninvasively and in real-time.

The software, developed by Xenogen Corp. More...
(Alameda, CA, USA), is called Living Image and was designed for Xenogen's IVIS imaging system 3D, but is also compatible with the company's IVIS imaging system 200. This new software provides more spatially accurate and quantitative data than the current software. It includes new tools that enable researchers to more precisely locate in 3D and quantify the signal strength of bioluminescent reporters (glowing tags that light up targeted biologic processes) in living animals.

The software includes a 3D analysis tool called DLIT, which the company claims is the first of its kind for determining the size, location, and brightness of the bioluminescent reporters and therefore creates a more spatially precise image. The first step in the DLIT process involves acquiring a laser-scanned structured light image, which the software processes to determine the surface shape (topography) of the animal. Second, a sequence of luminescent images is acquired through different light filters ranging in wavelength from 560-660 nm. Because the absorption of light in tissue is dependent on its wavelength, this spectrum helps spatially orient the location of the light source. Combined with the surface topography data, the software then analyzes and processes these images to determine the 3D location and shape of the bioluminescent reporter.

"Xenogen's new Living Image software 3D analysis package is a great addition to our portfolio because it improves upon the predictive quality of the data through enhanced localization of the light signal produced by our biophotonic imaging technology,” said Pamela R. Contag, Ph.D., president of Xenogen. "Using the new software, scientists can better pinpoint the location of tumors, as well as the effect of drugs on a tumor and the surrounding tissue.”

Xenogen holds exclusive patent rights to the fundamental technology for real-time in vivo biophotonic imaging. The company incorporated the bioluminescent gene that generates a firefly glow into the microorganisms it uses as biological tags.




Related Links:
Xenogen

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.